Serial No.: 09/700,057 Filed: February 5, 2001

riicu. re

Page 2

In the Claims:

The list of claims will replace all prior versions and listings of claims in the

application:

1-22. (Canceled)

23. (Currently Amended) A method of reducing the incidence of post-operative

adhesions in a body cavity, comprising introducing into the body cavity a composition

comprising an aqueous formulation further comprising a polysaccharide dextrin in an amount

effective to reduce the incidence of said post-operative adhesions, wherein the dextrin is

unsubstituted and the dextrin contains more than 15% of polymers with a degree of

polymerisation polymerization (DP) greater than 12 and acts as an osmotic agent to maintain

a volume of the aqueous formulation in the body cavity serving to separate tissues which

otherwise may adhere to each other, and wherein the aqueous formulation is a solution in the

body cavity and remains in the body cavity for at least 2 days.

24-25. (Canceled)

26. (Previously Presented) A method according to Claim 23 wherein said

composition is applied to the appropriate body cavity after a surgical operation has been

carried out.

27. (Currently Amended) A method according to Claim 23 wherein the solution is

allowed to remain aqueous formulation remains in the body cavity for a minimum of 2 to 3

days.

28. (Currently Amended) A method according to Claim 23 wherein the solution is

allowed to remain aqueous formulation remains in the body cavity over the period during

which fibrin exudation is at a maximum.

Serial No.: 09/700,057

Filed: February 5, 2001

Page 3

29. (Currently Amended) A method according to Claim 23 wherein the solution aqueous formulation remains in the body cavity for a period of up to 7 to 8 days in order to

allow restoration of non-stick surfaces.

30. (Previously Presented) A method according to Claim 23 wherein the

composition is applied to the body cavity in a volume in the range of 500-2000 ml.

31. (Currently Amended) A method according to Claim 23 [[30]] wherein the

composition is applied to the body cavity in a volume in the range of 1000 ml-1500 ml.

32. (Previously Presented) A method according to Claim 23 wherein the dextrin

is applied to the appropriate body cavity in differing concentrations over a concentration

range of 2.5-18 % weight to volume of the composition.

33. (Previously Presented) A method according to Claim 32 wherein the dextrin

is applied to the appropriate body cavity in differing concentrations over a concentration

range of 3-5 % weight to volume of the composition.

34. (Previously Presented) A method according to Claim 32 wherein the dextrin

is applied to the appropriate body cavity in an amount of about 4 % weight to volume of the

composition.

35. (Previously Presented) A method according to Claim 23 wherein the

concentration range of the dextrin is selectively altered over a period of time.

36-44. (Canceled)

45. (Currently Amended) A method according to Claim 23 wherein the solution

aqueous formulation remains in the body cavity for a period of up to 3 to 4 days in order to

allow restoration of non-stick surfaces.

Serial No.: 09/700,057 Filed: February 5, 2001

Page 4

46. (Currently Amended) A method according to Claim 23 wherein the solution

aqueous formulation largely holds in place over the period the solution aqueous formulation

resides in the body cavity.

47. (Previously Presented) A method according to Claim 23 wherein the body

cavity is a peritoneal cavity.

48. (Previously Presented) A method according to Claim 26 wherein the

appropriate body cavity is a peritoneal cavity.

49. (Previously Presented) A method according to Claim 45 wherein the body

cavity is a peritoneal cavity.

50. (Previously Presented) A method according to Claim 46 wherein the body

cavity is a peritoneal cavity.

51. (Currently Amended) A method of reducing the incidence of post-operative

adhesions in a body cavity, comprising introducing into the body cavity a composition

comprising an aqueous formulation further comprising a polysaccharide dextrin in an amount

effective to reduce the incidence of said post-operative adhesions, wherein the dextrin is

unsubstituted and the dextrin contains more than 15% of polymers with a degree of

polymerisation polymerization (DP) greater than 12 and acts as an osmotic agent to maintain

a volume of the aqueous formulation in the body cavity serving to separate tissues which

otherwise may adhere to each other, and wherein:

(a) the aqueous formulation is a solution in the body cavity, and remains in the body

cavity for at least 2 days and is not removed:

(b) the dextrin is applied to the body cavity in an amount of about 4 % weight to

volume of the composition; and

(c) the composition is administered intraperitoneally.

Serial No.: 09/700,057

Filed: February 5, 2001

Page 5

52. (New) The method of claim 23 wherein the composition is introduced into the body cavity when the operation is an abdominal operation.

53. (New) The method of claim 23 wherein the composition is introduced into the body cavity when the operation is a gynecological operation.

54. (New) The method of claim 34 wherein the body cavity is a peritoneal cavity.

55. (New) The method of claim 51 wherein the body cavity is a peritoneal cavity.

56. (New) The method of claim 51 wherein the composition is introduced into the body cavity after an abdominal operation has been carried out.

57. (New) A method of reducing the incidence of post-operative adhesions in a body cavity, comprising:

(a) introducing into the body cavity a composition comprising an aqueous formulation further comprising a polysaccharide dextrin in an amount effective to reduce the incidence of said post-operative adhesions, wherein the dextrin is unsubstituted and the dextrin contains more than 15% of polymers with a degree of polymerization (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other, and wherein the aqueous formulation is a solution in the body cavity; and

(b) allowing the aqueous formulation to remain in the body cavity for at least 2 days, wherein the aqueous formulation is not removed from the body cavity.

58. (New) The method of claim 57 wherein body cavity is a peritoneal cavity.

59. (New) The method of claim 57 wherein the composition is introduced into the body cavity when the operation is an abdominal operation.

Serial No.: 09/700,057

Filed: February 5, 2001

Page 6

60. (New) The method of claim 57 wherein the composition is introduced into the body cavity when the operation is a gynecological operation.

- 61. (New) The method of claim 57 wherein said composition is applied to the appropriate body cavity after a surgical operation has been carried out.
- 62. (New) The method of claim 57 wherein a volume of the aqueous formulation remains in the body cavity for a minimum of 2 to 3 days.
- 63. (New) The method of claim 57 wherein the composition is applied to the body cavity in a volume in the range of 500-2000 ml.
- 64. (New) The method of claim 57 wherein the composition is applied to the body cavity in a volume in the range of 1000 ml-1500 ml.
- 65. (New) The method of claim 57 wherein the dextrin is applied to the appropriate body cavity in an amount of about 4 % weight to volume of the composition.
 - 66. (New) The method of claim 65 wherein the body cavity is a peritoneal cavity.
- 67. (New) A method of reducing the incidence of post-operative adhesions in a body cavity, comprising introducing into the body cavity a composition comprising an aqueous formulation further comprising a polysaccharide dextrin in an amount effective to reduce the incidence of said post-operative adhesions, wherein the dextrin is unsubstituted and the dextrin contains more than 15% of polymers with a degree of polymerization (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may adhere to each other, and wherein the aqueous formulation is a solution in the body cavity administered under surgical conditions and the aqueous formulation remains in the body cavity and is not removed.
 - 68. (New) The method of claim 67 wherein the body cavity is a peritoneal cavity.

Serial No.: 09/700,057

Filed: February 5, 2001

Page 7

69. (New) The method of claim 67 wherein the surgical condition is an abdominal surgery.

- 70. (New) The method of claim 67 wherein the surgical condition is a gynecological surgery.
- 71. (New) The method of claim 67 wherein said composition is applied to the appropriate body cavity after a surgical operation has been carried out.
- 72. (New) The method of claim 67 wherein the aqueous formulation remains in the body cavity for a minimum of 2 to 3 days.
- 73. (New) The method of claim 67 wherein the composition is applied to the body cavity in a volume in the range of 500-2000 ml.
- 74. (New) The method of claim 67 wherein the composition is applied to the body cavity in a volume in the range of 1000 ml-1500 ml.
- 75. (New) The method of claim 66 wherein the dextrin is applied to the appropriate body cavity in an amount of about 4 % weight to volume of the composition.
 - 76. (New) The method of claim 75 wherein the body cavity is a peritoneal cavity.
- 77. (New) A method of reducing the incidence of post-operative adhesions in a body cavity, comprising introducing into the body cavity a composition comprising less than 2000 ml of an aqueous formulation further comprising a polysaccharide dextrin in an amount effective to reduce the incidence of said post-operative adhesions, wherein the dextrin is unsubstituted and the dextrin contains more than 15% of polymers with a degree of polymerization (DP) greater than 12 and acts as an osmotic agent to maintain a volume of the aqueous formulation in the body cavity serving to separate tissues which otherwise may

Serial No.: 09/700,057

Filed: February 5, 2001

Page 8

adhere to each other, and wherein the aqueous formulation is a solution in the body cavity and the aqueous formulation remains in the body cavity and is not removed.

- 78. (New) The method of claim 77 wherein the composition is introduced into the body cavity when the operation is an abdominal operation.
- 79. (New) The method of claim 77 wherein the composition is introduced into the body cavity when the operation is a gynecological operation.
- 80. (New) The method of claim 77 wherein said composition is applied to the appropriate body cavity after a surgical operation has been carried out.
- 81. (New) The method of claim 77 wherein at least a portion of the volume of the aqueous formulation remains in the body cavity for a minimum of 2 to 3 days.
- 82. (New) The method of claim 77 wherein the dextrin is applied to the appropriate body cavity in an amount of about 4 % weight to volume of the composition.
 - 83. (New) The method of claim 82 wherein the body cavity is a peritoneal cavity.